Company news: Doximity, Jazz Pharmaceuticals

Share this article:
The medical social network Doximity has raised $17 million in series B financing, reported MedCity News. CEO Jeff Tangney told the publication the money would be used to “scale the network and expand our offerings.” The company's network provides a secure environment in which professionals can discuss patient cases and exchange patient information. The series B financing brings company funding to $27 million. Doximity says 1 in 7 US doctors are in its network.

Jazz Pharmaceuticals is putting some distance between itself and the women's healthcare business it scooped up when it purchased Azur in 2011. The company announced Thursday that it is selling the six products, which include the prenatal vitamins Natelle One and Gesticare DHA, to specialty company Meda. The transaction includes a $95 million sale price, as well as the transfer of about 60 employees from Jazz to Meda. Analysts Corey Davis of Jefferies and Michael Faerm supported the sale in their respective September 6 research notes. Both wrote that the women's drugs weren't a solid fit with Jazz's scope, with Faerm adding that the deal scuttles a roster of products that have margins “well below co. average. Faerm attributed the lower margin to the promotional costs: sales ratio, which he estimated to be about 50 sales reps for $30 million in sales.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.